• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 29, 2016

View Archived Issues

My, my American pie: Xencor's Novartis pact slices nicely, up to $2.4B+ for non-U.S. rights

Xencor Inc.'s broadly enabling platform made possible "the calculated trade-off" by Novartis AG that let his bispecific antibody firm hang onto U.S. rights for its pair of lead compounds in a deal that could be worth as much as $2.4 billion-plus, CEO Bassil Dahiyat told BioWorld Today. Read More

Gilead captures approval for pan-genotypic HCV therapy

Gilead Sciences Inc. landed an on-schedule FDA approval for the chronic hepatitis C virus (HCV) drug Epclusa, the first drug effective against all six major genotypes of the virus. The fixed-dose combination tablet contains both the active ingredient of Sovaldi (sofosbuvir) and the new NS5A inhibitor velpatasvir. Read More

Celyad shares drop 40% on cell therapy phase III miss in heart failure

DUBLIN – Shares in Celyad SA fell 40 percent in Brussels Tuesday on news that its C-Cure stem cell therapy failed to reach the primary endpoint of a phase III trial in patients with congestive heart failure. Read More

Studies highlight hope for Zika vaccine, worry for virus in pregnancy

LONDON – The prospects of developing an effective Zika vaccine are improving, with the first report of effective immunization in a mouse challenge model, and data from the first nonhuman primate model of Zika showing that infection confers subsequent immunity. Read More

Regulus retreads jaundice scare, triggering clinical hold

A serious new case of jaundice that developed during a Regulus Therapeutics Inc. study of RG-101 for the treatment of chronic hepatitis C virus (HCV) triggered the FDA to issue a verbal clinical hold on the program, sending company shares (NASDAQ:RGLS) down 49.3 percent to $2.54 on Tuesday. Read More

Tweaks possible for CMS' Part B demonstration

Despite congressional demands that CMS withdraw a controversial Part B demonstration model, the agency seems bent on finalizing the rule that would establish the nationwide experiment, possibly with some tweaks. Read More

Biocon, Quark move forward on trials for NAION treatment

NEW DELHI – Working with a U.S. partner, one of India's most active biopharma companies, Biocon Ltd., is moving forward on late-stage trials for a drug aimed at treating a common eye disorder for which there is no marketed treatment. Read More

Financings

JDP Therapeutics Inc., of Blue Bell, Pa., said it secured up to $17 million in series A financing led by China-based Cosci Med-Tech Co. Ltd. Read More

Other news to note

Xbiotech Inc., of Austin, Texas, entered an exclusive licensing agreement with Megapharm Ltd., of Raanana, Israel, to commercialize Xilonix in Israel for the treatment of advanced colorectal cancer. Read More

In the clinic

Aytu Bioscience Inc., of Englewood, Colo. said clinical data for Natesto (testosterone), a nasal gel approved as a replacement therapy for men diagnosed with hypogonadism, has shown that the pharmacokinetics, safety and efficacy of Natesto for restoring normal testosterone levels in men with low testosterone levels is not adversely affected by seasonal allergies. Read More

Regulatory front

As part of the U.S. cancer moonshot, the Patent and Trademark Office is implementing a one-year pilot program Wednesday to provide for earlier review of patent applications pertaining to cancer immunotherapy. To qualify for the 12-month review, applications must claim a method of treating a cancer using immunotherapy, and the applicant must file a grantable "petition to make special" before June 29, 2017. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe